Abstract
Major breast cancer predisposition genes, only account for approximately 30% of high-risk breast cancer families and only explain 15% of breast cancer familial relative risk. The HGF growth factor receptor MET is potentially functionally altered due to an uncommon germline single nucleotide polymorphism (SNP), MET-T1010I, in many cancer lineages including breast cancer where the MET-T1010I SNP is present in 2% of patients with metastatic breast cancer. Expression of MET-T1010I in the context of mammary epithelium increases colony formation, cell migration and invasion invitro and tumor growth and invasion in-vivo. A selective effect of MET-T1010I as compared to wild type MET on cell invasion both in-vitro and in-vivo suggests that the MET-T1010I SNP may alter tumor pathophysiology and should be considered as a potential biomarker when implementing MET targeted clinical trials.
Original language | English (US) |
---|---|
Pages (from-to) | 2604-2614 |
Number of pages | 11 |
Journal | Oncotarget |
Volume | 6 |
Issue number | 5 |
DOIs | |
State | Published - 2015 |
Keywords
- Breast cancer
- MET mutations
- Malignant transformation
ASJC Scopus subject areas
- Oncology
MD Anderson CCSG core facilities
- Advanced Technology Genomics Core
- Bioinformatics Shared Resource
- Biostatistics Resource Group
- Research Animal Support Facility
- Tissue Biospecimen and Pathology Resource
- Cytogenetics and Cell Authentication Core
- Clinical Trials Office